We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has approved a once-daily ...

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...

Farxiga is a prescription oral tablet used to manage type 2 diabetes or certain heart or kidney conditions. It’s a brand-name drug with the active ingredient dapagliflozin. Farxiga tablets come in ...

The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) met its primary endpoint in the DELIVER phase III trial by significantly lowering the risk of cardiovascular death or ...

NEW ORLEANS, LA—Ever since sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to have beneficial effects in patients with heart failure, there have been questions about the underlying ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest ...

First Phase 3 data for dapagliflozin, a novel SGLT2 Inhibitor, presented at EASD VIENNA--(BUSINESS WIRE)--Results from a 24-week phase 3 clinical study demonstrated that the investigational drug ...

Dapagliflozin substantially slowed the progression of chronic kidney disease (CKD) in patients with immunoglobulin A nephropathy, according to a new study. Treatment with dapagliflozin substantially ...

Please provide your email address to receive an email when new articles are posted on . A combination of the glucagon-like peptide-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin is ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at observing the clinical effects of sacubitril/valsartan combined with dapagliflozin ...

The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. We randomly ...